SCHEMBL4320733

SCHEMBL4320733

CC(=O)N1CCN(c2ccc(/C=C/c3n[nH]c4ccccc34)c(NC(=O)c3sccc3C)c2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 5/20 0.60
AURKB Q96GD4 5/20 0.60
FLT3 P36888 5/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MAPT P10636 3/20 0.39
ALDH1A1 P00352 1/20 0.39
CDK1 P06493 2/20 0.38
CCNB1 P14635 2/20 0.38
GFER P55789 2/20 0.37
LMNA P02545 2/20 0.37
MEN1 O00255 1/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
ATM Q13315 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
FGFR1 P11362 2/20 0.36
FLT1 P17948 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4320741 1.00 AURKA (0.60) AURKAAURKBFLT3NPC1RAB9A
SCHEMBL5265469 0.94 AURKA (0.60) AURKAAURKBFLT3NPC1RAB9A
SCHEMBL4314905 0.93 AURKA (0.58) AURKAAURKBFLT3NPC1RAB9A
SCHEMBL4314913 0.93 AURKA (0.58) AURKAAURKBFLT3NPC1RAB9A
SCHEMBL4326955 0.91 AURKA (0.58) AURKAAURKBFLT3NPC1RAB9A
SCHEMBL4326949 0.91 AURKA (0.58) AURKAAURKBFLT3NPC1RAB9A
SCHEMBL4316361 0.90 AURKA (0.56) AURKAAURKBFLT3NPC1RAB9A
SCHEMBL4316358 0.90 AURKA (0.56) AURKAAURKBFLT3NPC1RAB9A
SCHEMBL4313585 0.89 AURKA (0.60) AURKAAURKBNPC1RAB9AMAPT
SCHEMBL4315080 0.89 AURKA (0.59) AURKAAURKBNPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885FLT3 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.